Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chuanqi Zhennaoning is a Traditional Chinese Medicine (TCM) formulation developed by Wuhan Pharmaceutical Valley Technology Development Co., Ltd., primarily indicated for the treatment of migraines and various types of headaches, including tension and vascular headaches. The formulation is a combination of several herbal extracts, including *Ligusticum striatum* (Chuanxiong), *Angelica dahurica* (Baizhi), *Asarum sieboldii* (Xixin), *Gypsum fibrosum* (Shigao), *Nardostachys jatamansi* (Gansong), and *Ziziphus jujuba* (Suanzaoren). Its therapeutic effects are attributed to the synergistic action of these components, which are traditionally used to promote blood circulation, dispel wind, and alleviate pain. It is commonly used in China to manage symptoms such as dizziness, nausea, and throbbing pain associated with migraine attacks.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chuanqi Zhennaoning.